Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-PD-1 (Programmed Death-1) antibody and application thereof

A PD-1 and antibody technology, applied in the direction of antibodies, applications, anti-inflammatory agents, etc., can solve the problem of low response rate and achieve the effects of high activity, low production cost, and high binding affinity

Active Publication Date: 2017-03-22
LUNAN PHARMA GROUP CORPORATION
View PDF13 Cites 41 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although a variety of monoclonal antibodies against immune checkpoints such as PD-1, PD-L1 and CTLA4 have been used clinically, the response rate of these antibodies as a single drug is still low, with an average of only 15-20%

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-PD-1 (Programmed Death-1) antibody and application thereof
  • Anti-PD-1 (Programmed Death-1) antibody and application thereof
  • Anti-PD-1 (Programmed Death-1) antibody and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0049] Abbreviations and Definitions

[0050] hPD-1 human PD-1 protein

[0051] CDR Complementarity-determining region in the variable region of an immunoglobulin defined by the Kabat numbering system

[0052] EC 50 Concentration that produces 50% efficacy or binding

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an antibody specifically combined with PD-1 (Programmed Death-1) with high affinity, and also provides a nucleic acid molecule for coding the antibody, an expression vector and a host cell for expressing the antibody, and a production method of the antibody. In addition, the invention also provides an immune conjugate and a medicinal composition containing the antibody, and application of the antibody to the preparation of a medicine for treating multiple diseases (including a cancer, an infectious disease and an inflammatory disease).

Description

technical field [0001] The present invention belongs to the field of therapeutic monoclonal antibodies, more specifically, the present invention relates to an antibody against programmed death receptor (PD-1); , inflammatory diseases). Background technique [0002] Programmed Death-1 (PD-1), a member of the CD28 family, is an immunosuppressive receptor expressed on the surface of activated T cells and B cells (Yao Zhu et al., Nat Rev Drug Discov, 2013; 12(2):130-146), originally obtained by subtractive hybridization in apoptotic T-cell hybridomas. PD-1 is mainly expressed in CD 4+ T cells, CD 8+ The surface of T cells, NK-T cells, B cells and activated monocytes is mainly induced by T cell receptor (TCR) or B cell receptor (BCR) signaling, and TNFα can enhance the expression of PD-1 on the surface of these cells (Francisco LM et al., Immunol Rev, 2010; 236:219-242). The PD-1 molecule consists of an extracellular domain, a transmembrane domain and an intracellular domain...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C07K16/46C12N15/13C12P21/02A61K39/395A61P35/00A61P31/00A61P31/14A61P31/04A61P31/20A61P31/18A61P33/00A61P29/00
CPCC07K16/2818C07K16/468A61K2039/505C07K2317/24C07K2317/565C07K2317/56C07K2317/92A61P35/00A61K39/395C07K16/2803C07K16/30A61K47/55C07K16/22C07K16/2863C07K16/2878C07K16/2887C07K16/32
Inventor 李强孙见宇郑云程杨璐马心鲁李媛丽
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com